American pharmaceutical firm Eli Lilly has announced that it will delay its clinical trial activities in the wake of the Covid-19 pandemic.

With the novel coronavirus (Covid-19) putting healthcare systems under strain, Lilly has decided to delay most new study starts, as well as pause enrolment in the majority of ongoing studies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The global healthcare system has been impacted by the coronavirus pandemic, leading to the restructuring of operations by many healthcare firms to prioritise caring for those suffering from the virus.

Lilly chief medical officer Tim Garnett said: “Lilly is working hard to alleviate some of the pressure that the global Covid-19 pandemic has placed on our healthcare system.

“We have repurposed our laboratories to conduct diagnostic testing for patients and we are researching potential therapeutics. In the interest of helping to ensure patient safety and minimising further stress on the system, Lilly has also decided to take several proactive steps in regard to our clinical trial activities around the world during the Covid-19 pandemic.

“By delaying most new study starts and pausing enrollment of new patients or healthy volunteers in most ongoing studies, we hope to ease the burden on participating healthcare facilities and allow physicians to focus more of their efforts on combating Covid-19.”

Despite disruption caused by the coronavirus, Lilly does not anticipate any adjustments to the previously communicated timelines for ongoing late-stage studies, except for mirikizumab, which is indicated for treating gastrointestinal (GI) disorders.

Last month, Eli Lilly reported top-line data from the Phase II/III DIAN-TU clinical trial of solanezumab in patients with autosomal dominant Alzheimer’s disease/dominantly inherited Alzheimer’s disease (DIAD) caused by rare gene mutations.

In January this year, Eli Lilly and Incyte reported positive data from the Phase III BREEZE-AD4 clinical trial performed to assess a combination of baricitinib and topical corticosteroids (TCS) for moderate to severe atopic dermatitis (AD).

Meanwhile, the Covid-19 death toll has reached 15,298 worldwide. A total of 349,187 confirmed cases and 100,338 recoveries have been reported to date.